LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

31.27 0.06

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

31.22

Máximo

31.3

Métricas clave
By Trading Economics
Ingresos	11M 64M
Ventas	-3.2M 149M
P/B Media del Sector	18.069 50.102
BPA	0.79
Margen de beneficios	42.663
Empleados	182
EBITDA	2M 83M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+3.75% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	285M 3.8B
Apertura anterior	31.21
Cierre anterior	31.27

Noticias sobre sentimiento de mercado

By Acuity

78%

22%

306 / 344 Clasificación en Healthcare

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 jun 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 jun 2026, 23:38 UTC

Adquisiciones, fusiones, absorciones

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 jun 2026, 23:01 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 23:01 UTC

Charlas de Mercado

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 jun 2026, 22:08 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Adquisiciones, fusiones, absorciones

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 jun 2026, 21:55 UTC

Adquisiciones, fusiones, absorciones

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 jun 2026, 21:53 UTC

Charlas de Mercado

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 jun 2026, 21:22 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

1 jun 2026, 20:46 UTC

Adquisiciones, fusiones, absorciones

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 jun 2026, 20:22 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Declares $11 Special Div

1 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 jun 2026, 19:40 UTC

Charlas de Mercado

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 jun 2026, 19:28 UTC

Charlas de Mercado

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 jun 2026, 19:01 UTC

Charlas de Mercado

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 jun 2026, 18:58 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 jun 2026, 18:54 UTC

Adquisiciones, fusiones, absorciones

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 jun 2026, 18:33 UTC

Charlas de Mercado

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 jun 2026, 18:32 UTC

Charlas de Mercado

Precious Metals Fall to Start June -- Market Talk

1 jun 2026, 18:00 UTC

Adquisiciones, fusiones, absorciones

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 jun 2026, 17:18 UTC

Charlas de Mercado

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 jun 2026, 17:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 17:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

3.75% repunte

Estimación a 12 Meses

Media 32.4 USD 3.75%

Máximo 35 USD

Mínimo 31.5 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

306 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.